Nu Skin Enterprises launches the new ageLOC Future Serum

Nu Skin Enterprises, Inc. (NYSE: NUS) introduced the new ageLOC Future Serum to more than 10,000 sales representatives at its launch event in Japan. Japanese distributors were eager to be in the first market to fully launch one of the company's new ageLOC skin care products that targets the sources of aging by resetting youth gene clusters to a more youthful pattern. The ageLOC products are marketed as 'genLOC' in Japan.

"We continue to believe that ageLOC will be the biggest global product launch in Nu Skin history and are pleased to begin the roll out in Japan," said Truman Hunt, Nu Skin president and chief executive officer. "We are committed to fueling the positive trends we are seeing in Japan and believe that the introduction of ageLOC will help in generating distributor enthusiasm in this important market. Our proprietary ageLOC products enable our sales representatives to take advantage of the accelerating growth in the anti-aging industry, which is expected to grow by 73 percent in Japan by 2015. We'll continue the global roll out of ageLOC next month as we launch new ageLOC skin care products in the United States, Europe and Latin America."

SOURCE Nu Skin Enterprises, Inc.

Comments

  1. Bill Bill United States says:

    This is one of the most significant product developments, launches in our lifetime.  I am amazed at how quickly the future serum works!
    Live with Intention, Bill, 1-888-891-4878

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease